gsk braf inhibitor | GSK announces headline results for Phase III stud

Keyword	CPC	PCC	Volume	Score	Length of keyword
gsk braf inhibitor	1.21	0.7	8165	99	18
gsk	1.96	0.9	4669	64	3
braf	1.69	0.1	6183	74	4
inhibitor	0.94	0.2	9399	97	9

Keyword	CPC	PCC	Volume	Score
gsk braf inhibitor	0.25	1	9793	95

Search Results related to gsk braf inhibitor on Search Engine

GSK announces headline results for Phase III study of the …
gsk.com

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-results-for-phase-iii-study-of-the-combination-of-tafinlar-dabrafenib-and-mekinist-trametinib-in-metastatic-melanoma/

WEBGlaxoSmithKline plc [LSE/NYSE: GSK] today announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib), compared to single agent therapy with Tafinlar in patients with BRAF V600 E or K mutation positive unresectable or metastatic melanoma, met its primary endpoint of Progression Free Survival (PFS ...

DA: 18 PA: 85 MOZ Rank: 18

GSK gains accelerated FDA approval for combination use of …
gsk.com

https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/

WEBGlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has …

DA: 15 PA: 92 MOZ Rank: 34

BRAF — a tumour-agnostic drug target with lineage-specific
nature.com

https://www.nature.com/articles/s41571-023-00852-0

WEBJan 26, 2024 · The FDA-approved BRAF inhibitors vemurafenib, dabrafenib and encorafenib selectively inhibit activated BRAF V600E/K/R/D monomers (class I BRAF mutants) in cancer cells, which underlies...

DA: 54 PA: 52 MOZ Rank: 9

GlaxoSmithKline announces start of two phase III studies in ... - GSK
gsk.com

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-start-of-two-phase-iii-studies-in-advancedmetastatic-melanoma/

WEBThe BRF113683 Phase III study compares GSK’436, a BRAF inhibitor, to dacarbazine (DTIC) in previously untreated patients with BRAF V600 mutated advanced or metastatic melanoma. The METRIC study compares GSK’212, a MEK inhibitor, to chemotherapy (DTIC or paclitaxel) in advanced or metastatic melanoma patients with a BRAF V600 …

DA: 40 PA: 34 MOZ Rank: 42

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1210093

WEBNov 1, 2012 · In an attempt to delay resistance to BRAF inhibition and explore the safety of combination therapy with BRAF and MEK inhibition, we conducted a phase 1 and 2 study to investigate the combination...

DA: 48 PA: 98 MOZ Rank: 51

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1203421

WEBJul 12, 2012 · A Phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor.

DA: 82 PA: 69 MOZ Rank: 47

Improved Overall Survival in Melanoma with Combined …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1412690

WEBJan 1, 2015 · The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining...

DA: 89 PA: 83 MOZ Rank: 59

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA …
nature.com

https://www.nature.com/articles/d41573-022-00117-y

WEB06 July 2022. BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval. By. Asher Mullard. Novartis’s combination of dabrafenib and trametinib has secured accelerated approval from...

DA: 11 PA: 56 MOZ Rank: 6

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080616/

WEBThe advent of combination therapy with BRAF and MEK inhibitors has eliminated many of the initial concerns associated with BRAF inhibitor monotherapy; evidence demonstrates both improved side effect profiles and prolonged clinical endpoints like ORR and PFS.

DA: 82 PA: 71 MOZ Rank: 42

Challenges and Opportunities in the Crusade of BRAF Inhibitors: …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413849/

WEBAug 8, 2023 · Serine/threonine-protein kinase B-Raf (BRAF; RAF = rapidly accelerated fibrosarcoma) plays an important role in the mitogen-activated protein kinase (MAPK) signaling cascade. Somatic mutations in the BRAF gene were first discovered in 2002 by Davies et al., which was a major breakthrough in cancer research.

DA: 97 PA: 38 MOZ Rank: 60